Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

Based on PK modeling, the Company expects that a human half-life of 50 days or more will support dosing every six months whereas a half-life of 75 days or more could support dosing once per year. In ...

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

Announcing a new publication for Acta Materia Medica journal. Psoriasis is a chronic inflammatory disorder for which phosphodiesterase-4 (PDE4) inhibitors have emerged as promising therapeutic agents ...

The primary endpoint was met, with 57% of subjects treated with the therapy achieving clear or almost clear skin.

Shares of Johnson & Johnson (JNJ) were in the spotlight on Friday morning after the company announced positive results from ...

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16Icotrokinra continues to ...

Pronounced “soh-TIK-too,” SOTYKTU is a once-daily pill for adults with moderate to severe plaque psoriasis that works inside ...

Using an existing steroid-free topical foam daily significantly improved the signs and symptoms of psoriasis on the scalp and ...

FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...